Chart, Financials, Historical Prices, Industry, Insider, Messages, Options, Profile, Reports, Research, SEC Filings, more...

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 9-Feb-2010
New Screen 

All Reports | Brokerage Reports | Independent Reports
All Reports (Showing 1 to 10 of 36)
Release
Date [down]		 Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
9-Feb-10New Constructs, LLCN/AKG: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings19$10  View Abstract
9-Feb-10Pechala's ReportsLubomir PechalaKING PHARMACEUTICALS INC (KG=US) - REPORT FOR ACTIVE TRADERS4$25  View Abstract
9-Feb-10ValuEngine, Inc.N/AValuEngine Industry Report for DRUGS18$49  View Abstract
9-Feb-10Stock Traders DailyThomas H. Kee Jr.Trading Report for (KG). A detailed Technical Analysis + Trading Plans for Day Trading, Swing Trading, and Long Term proactive investments in (KG).5$18  View Abstract
8-Feb-10Plunkett Research, Ltd.Jack W. PlunkettBiotechnology & Genetics Industry Market Research and Competitive Analysis 2010569$299  View Abstract
8-Feb-10Plunkett Research, Ltd.Jack W. PlunkettBiotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary)71$199  View Abstract
8-Feb-10ValuEngine, Inc.N/AValuEngine Detailed Valuation Report for KG13$25  View Abstract
8-Feb-10Market EdgeN/AMarket Edge Equity Research Report4$10  View Abstract
8-Feb-10PriceTarget Research, Inc.N/AKing Pharmaceuticals has a current Overall Rating of C (Neutral).7$25  View Abstract
7-Feb-10Wright ReportsN/AWright Industry Averages: Health, Medicine and Pharmaceuticals (Global)144$169  View Abstract
Next 20
Brokerage Reports (Showing 1 to 3 of 3)
Release
Date [down]		 Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
20-Jan-10Collins Stewart LLCLouise ChenFebruary 2010 Catalyst Calendar25$75  View Abstract
15-Jan-10Collins Stewart LLCLouise ChenReiterating Buy and Increasing Price Target after Management Meeting4$10  View Abstract
13-Jan-10Thomson StreetEventsN/AKG - Event Transcript of King Pharmaceuticals conference call, Jan. 13, 2010 / 2:30pm ET6$75  View Abstract
Independent Reports (Showing 1 to 10 of 33)
Release
Date [down]		 Contributor Author Title Pages Price More Info
9-Feb-10New Constructs, LLCN/AKG: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings19$10View Abstract
9-Feb-10Pechala's ReportsLubomir PechalaKING PHARMACEUTICALS INC (KG=US) - REPORT FOR ACTIVE TRADERS4$25View Abstract
9-Feb-10ValuEngine, Inc.N/AValuEngine Industry Report for DRUGS18$49View Abstract
9-Feb-10Stock Traders DailyThomas H. Kee Jr.Trading Report for (KG). A detailed Technical Analysis + Trading Plans for Day Trading, Swing Trading, and Long Term proactive investments in (KG).5$18View Abstract
8-Feb-10Plunkett Research, Ltd.Jack W. PlunkettBiotechnology & Genetics Industry Market Research and Competitive Analysis 2010569$299View Abstract
8-Feb-10Plunkett Research, Ltd.Jack W. PlunkettBiotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary)71$199View Abstract
8-Feb-10ValuEngine, Inc.N/AValuEngine Detailed Valuation Report for KG13$25View Abstract
8-Feb-10Market EdgeN/AMarket Edge Equity Research Report4$10View Abstract
8-Feb-10PriceTarget Research, Inc.N/AKing Pharmaceuticals has a current Overall Rating of C (Neutral).7$25View Abstract
7-Feb-10Wright ReportsN/AWright Industry Averages: Health, Medicine and Pharmaceuticals (Global)144$169View Abstract
Next 20

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.